Skip to main content


A first for Europe: The Prostate Cancer Registry

A first for Europe: The Prostate Cancer Registry

Vienna, Austria, 28 September, 2015 – Janssen presented data from the first analysis of The Prostate Cancer Registry at the 2015 European Cancer Congress (ECC) in Vienna, Austria. The Registry is the first and largest prospective study of patients with metastatic castration-resistant prostate cancer (mCRPC) in Europe. It aims to provide real world data to help improve the quality of care for men with mCRPC.

With the aim of enrolling a total of 3,000 patients, to date more than 2,500 mCRPC patients from 192 centres in 16 European countries have so far been enrolled. Patients in the study will be followed for up to three years. By collecting real world data from such a large patient population in both oncology and urology clinics, the Registry has the capacity to address the key medical and scientific questions concerning the optimal care of mCRPC patients in routine practice, such as treatment sequencing, treatment outcomes, impact on quality of life, medical resource utilisation and patient safety.

Read the full press release here.